SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, today announced the completion of a $121 million Series C financing, bringing its total funding raised to date at $274 million. In addition to the participation of Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. Proceeds from the financing will be used to grow Cellarity’s talent base, strengthen its platform and advance its pipeline to the clinic.
“We welcome our new investors and appreciate the continued support of our current investors,” said Fabrice Chouraqui, PharmD, CEO of Cellarity and CEO-Partner at Flagship Pioneering. “By shifting the focus from a single target to the underlying cellular dysfunction, our platform unravels the complexity of disease biology to create drugs never before possible. We have already made significant progress in confirming the unique capability of our platform with the development of compounds that have been validated in vitro and in vivo, including in higher species. With this funding, we plan to advance our pipeline and showcase the immense possibilities of our approach.
To create medicines, Cellarity looks beyond individual molecular targets and instead focuses on the whole cell. The company uses single-cell technologies to identify cellular drivers during the transition from health to disease and applies proprietary deep learning models to create drugs that reverse disease at the cellular level. Cellarity has developed unique capabilities to link biology and chemistry with high-dimensional transcriptomic data to design drugs against the cellular signature of disease. The Cellarity platform provides critical insights into cellular dysfunction and reveals new biology with which we can treat a range of diseases, including those that currently lack a known drug target.
“Cellarity is truly rewriting the rules of drug creation. Disease is not driven by a mechanism or a protein, so Cellarity has developed the ability to solve disease through the lens of the whole cell,” said Stephen Berenson, Cellarity Board Chairman and Managing Partner. at Flagship Pioneering. “Because the cell is a more complete representation of disease, the platform is uniquely designed to increase translatability and clinical success, creating important new drugs for in-house pipeline development as well as with partners.
About the winery
Cellarity’s mission is to fundamentally rethink the way medicines are created. By shifting the focus from a single target to understanding the whole cell, Cellarity uncovers the complex biology of disease to create treatments never before possible. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single-cell technologies and machine learning to unravel the complex biology of disease and purposefully design breakthrough medicines. Because Cellarity’s drugs are created against many cellular disease factors rather than a single target, their approach is designed to improve clinical translatability and success and is applicable to a wide range of disease areas. The company currently has ongoing programs in several disease areas, including metabolic diseases, hematology and immuno-oncology. For more information, visit www.cellarity.com.
About Flagship Pioneering
Flagship Pioneering designs, creates, resources and grows best-in-class bioplatform companies to transform human health and sustainability. Since its launch in 2000, the company has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to create and foster more than 100 science-based projects, generating more than $100 billion in global value. . To date, Flagship has deployed more than $2.9 billion in capital for the creation and growth of its pioneering companies, as well as more than $19 billion in follow-on investments from other institutions. The current flagship ecosystem comprises 41 transformative companies, including Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA) and Seres Therapeutics (NASDAQ: MCRB).